TPA for Pharmaceutical Products: Complete Texture Profile Analysis ProtocolTPA pharmaceutical gel

TPA pharmaceutical gel testing — and TPA of creams, ointments, hydrogels, soft capsules, and even tablets — is a two-cycle compression test that extracts seven quantitative parameters from a single measurement: hardness, fracturability, cohesiveness, springiness, gumminess, chewiness, and resilience. Developed at MIT by Szczesniak and refined by Bourne in the 1970s, Texture Profile Analysis became the pharmaceutical industry's standard multi-parameter method for characterizing semi-solid and viscoelastic dosage forms.

A correctly configured TPA takes less than 90 seconds per sample, produces reproducibility under 5% CV on well-formulated gels, and generates a comprehensive mechanical fingerprint that single-compression methods cannot match. For pharmaceutical R&D, TPA accelerates formulation screening. For QC, TPA provides multi-dimensional release criteria that catch out-of-specification batches invisible to single-parameter tests.

What Is TPA and Why It Matters for Pharmaceutical Formulations

Texture Profile Analysis simulates the action of repeated compression — originally the first and second bite in sensory evaluation, but in pharmaceutical context the repeated mechanical stress a gel experiences during tube extrusion, a tablet during handling, or a capsule during packaging and transport. The test compresses a sample to a defined strain (typically 40–60% deformation), waits a defined hold period, releases, waits a defined recovery period, then compresses again to the same strain.

TPA is widely used for: pharmaceutical gels (hydrogels, carbopol gels, cellulose gels, alginate rafts), creams (O/W and W/O emulsions), ointments, hydrocortisone and other semi-solid topicals, soft gelatin capsules, suppositories, alginate raft-forming formulations (per British Pharmacopoeia), and occasionally tablets for comparing coating elasticity.

Why TPA matters in pharma: a single-compression test gives you one number. TPA gives seven correlated numbers that together characterize the sample's elasticity, plasticity, recovery behavior, and internal cohesion. For a topical hydrocortisone cream, hardness alone cannot distinguish a well-formulated cream from one that is over-thickened; cohesiveness and springiness do.

The 7 TPA Parameters: Definitions and Pharmaceutical Significance

Hardness (N) — the peak force recorded during the first compression cycle. For pharmaceutical gels, typical hardness ranges from 0.1N (thin hydrogels) to 15N (firm ointments). For tablets, hardness ranges 50–300N. A hardness drop over stability storage is a classic early-warning indicator of formulation degradation.

Fracturability (N) — the force at the first significant break in the force-time curve during the first compression. Many pharmaceutical gels do not fracture during TPA compression. For gels that do fracture, fracturability captures the brittle-to-plastic transition.

Cohesiveness (dimensionless, 0–1) — the ratio of the area under the second compression curve (A2) to the area under the first compression curve (A1). Values near 1.0 indicate highly cohesive samples that recover most of their internal structure; values near 0.2–0.5 indicate samples that yield structure irreversibly. Cohesiveness is one of the most discriminating TPA parameters for pharmaceutical formulation screening.

Springiness (dimensionless, 0–1) — the ratio of the distance the sample recovers between the two compression cycles to the compression distance on the first cycle. Pharmaceutical gels typically range 0.3–0.9; ointments 0.2–0.5; creams 0.3–0.6. Springiness is sensitive to changes in crosslink density, polymer molecular weight, and storage-induced syneresis.

Gumminess (N) — calculated as hardness × cohesiveness. Captures the resistance to disintegration during extrusion and spreading. Typical pharma hydrogel gumminess: 0.5–8 N.

Chewiness (N) — calculated as gumminess × springiness = hardness × cohesiveness × springiness. Most often reported for solid dosage forms (gummies, chewable tablets) rather than topical gels.

Resilience (dimensionless, 0–1) — the ratio of the work done by the sample during the first-compression withdrawal to the work done during the first-compression descent. A fast-response elastic parameter; detects early-stage structural recovery. Sensitive to crosslink density changes and useful for stability-indicating QC.

Setting Up a TPA Test on the KHT TA-30 (Speed, Distance, Trigger, Delay)

A reproducible pharmaceutical TPA requires six parameters to be locked down. Below is the standard protocol for pharmaceutical gels, creams, and ointments on the KHT TA-30.

Step 1. Select the probe. For pharmaceutical semi-solid TPA, the standard probe is a 35 mm or 40 mm flat cylindrical probe. For small-sample or high-throughput work, a 25 mm probe is acceptable provided it is held constant across the study.

Step 2. Prepare the sample. Transfer the gel, cream, or ointment into a standard 60 mm diameter × 25 mm deep sample cup, filling to within 2 mm of the rim. Avoid air bubbles. Equilibrate to 25.0 °C ± 0.5 °C.

Step 3. Configure test parameters on the KHT TA-30 software.

Step 4–8. Run the test: lower probe to surface, execute the double compression cycle, review the curve, extract parameters, repeat for n = 6 replicates minimum, export as CSV for LIMS intake or PDF for batch records.

Acceptance Criteria Setup — Typical Ranges for Pharmaceutical Gels

Below are representative TPA acceptance bands for common pharmaceutical semi-solid formulations. These are starting points; finalize via formulation-specific validation with at least three batches.

Interpreting TPA Curves for Gels, Creams, Tablets and Capsules

TPA interpretation is pattern recognition, not single-number comparison. Train QC analysts to read the shape of the curve, not just the derived parameters.

Healthy pharmaceutical gel curve: clean first-compression peak with smooth rise to Hardness; brief plateau during the 5 s hold; clean withdrawal with modest adhesion tail; full recovery to trigger position; second compression peak at 60–85% of the first peak magnitude. Cohesiveness in the 0.6–0.85 band, springiness in the 0.7–0.9 band. This is a well-crosslinked, elastically recovering gel.

Over-sheared or degraded cream: first compression is normal, but second compression peak is less than 30% of the first. Cohesiveness below 0.3. The emulsion has yielded irreversibly — common failure mode during stability storage, mechanical shear during manufacturing, or freeze-thaw cycling.

Brittle failure in soft capsule TPA: sharp fracture event during the first-compression rise, with force dropping to near-zero before the 50% strain target is reached. Softgel shells that become brittle during storage show this pattern.

Red flags on the curve: double peaks on the first compression (probe misalignment or sample heterogeneity); non-zero force during the delay period (sample extrusion around probe edge); second compression force exceeds first (sample settled during hold or temperature drift); ragged/noisy curve (trigger too low).

GMP Documentation: Setting Specification Limits and Batch Release Criteria

TPA data is only as useful as the regulatory documentation surrounding it. For GMP batch release, treat TPA like any other mechanical release test: document the method, validate the instrument, lock the SOP, and set specification bands with formal DOE.

Method validation: address specificity (does the method distinguish between intended formulation variants?), accuracy (reference standard TPA on certified gel materials), precision (intra-day and inter-day CV% across operators), linearity (if the method will be used across a concentration range), and robustness. Typical acceptance: CV% below 8% for hardness, below 12% for cohesiveness and springiness.

Specification band development: Build TPA specification bands from at least three validation batches of known-good formulation, supplemented by stress batches. Set initial acceptance bands at mean ± 3 SD from the pooled validated batch data, then narrow based on stability study outcomes.

21 CFR Part 11 documentation: Every TPA run recorded for GMP purposes must include timestamp (NIST-traceable), operator identity with electronic signature, method ID with version number, sample ID traceable to batch record, raw curve (not just derived parameters), operator review annotation, and reviewer approval signature. The KHT TA-30 pharma software enforces all of these as standard.

Stability study integration: Run TPA at every pull point on stored samples. Plot hardness, cohesiveness, and springiness over time. Trending these three parameters catches most physical stability failures earlier than single-parameter viscosity testing.